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Abstract
Introduction: Most cases of the 2009 influenza A (H1N1) infection are self-limited, but occasionally the disease
evolves to a severe condition needing hospitalization. Here we describe the evolution of the respiratory
compromise, ventilatory management and laboratory variables of patients with diffuse viral pneumonitis caused by
pandemic 2009 influenza A (H1N1) admitted to the ICU.
Method: This was a multicenter, prospective inception cohort study including adult patients with acute respiratory
failure requiring mechanical ventilation (MV) admitted to 20 ICUs in Argentina between June and September of
2009 during the influenza A (H1N1) pandemic. In a standard case-report form, we collected epidemiological
characteristics, results of real-time reverse-transcriptase–polymerase-chain-reaction viral diagnostic tests,
oxygenation variables, acid-base status, respiratory mechanics, ventilation management and laboratory tests.
Variables were recorded on ICU admission and at days 3, 7 and 10.
Results: During the study period 178 patients with diffuse viral pneumonitis requiring MV were admitted. They
were 44 ± 15 years of age, with Acute Physiology And Chronic Health Evaluation II (APACHE II) scores of 18 ± 7,
and most frequent comorbidities were obesity (26%), previous respiratory disease (24%) and immunosuppression
(16%). Non-invasive ventilation (NIV) was applied in 49 (28%) patients on admission, but 94% were later intubated.
Acute respiratory distress syndrome (ARDS) was present throughout the entire ICU stay in the whole group (mean
PaO2/FIO2 170 ± 25). Tidal-volumes used were 7.8 to 8.1 ml/kg (ideal body weight), plateau pressures always
remained < 30 cmH2O, without differences between survivors and non-survivors; and mean positive end-expiratory
pressure (PEEP) levels used were between 8 to 12 cm H2O. Rescue therapies, like recruitment maneuvers (8 to
35%), prone positioning (12 to 24%) and tracheal gas insufflation (3%) were frequently applied. At all time points,
pH, platelet count, lactate dehydrogenase assay (LDH) and Sequential Organ Failure Assessment (SOFA) differed
significantly between survivors and non-survivors. Lack of recovery of platelet count and persistence of leukocytosis
were characteristic of non-survivors. Mortality was high (46%); and length of MV was 10 (6 to 17) days.
Conclusions: These patients had severe, hypoxemic respiratory failure compatible with ARDS that persisted over
time, frequently requiring rescue therapies to support oxygenation. NIV use is not warranted, given its high failure
rate. Death and evolution to prolonged mechanical ventilation were common outcomes. Persistence of
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Introduction
On April 2009, a novel influenza A (H1N1) virus
emerged in Mexico and spread rapidly across the world
[1,2]. As of 17 June 2010, more than 214 countries had
reported confirmed cases of infection with pandemic
2009 influenza A (H1N1) virus, including at least 18,156
deaths [3]. Unlike seasonal influenza, in which hospitali-
zations occur among patients younger than 2 and older
than 65 years, or in those with underlying diseases [4],
this novel virus affected otherwise healthy young and
middle-aged adults and obese individuals [2,5]. Patients
with previous respiratory disease, immunocompromised
hosts and pregnant women were affected as frequently
as with seasonal influenza [6-15]. Although a mild form
of the disease was prevalent, it soon became evident
that the 2009 influenza A (H1N1) virus could also pro-
voke severe, acute respiratory failure requiring admis-
sion to the intensive care unit (ICU) for mechanical
ventilation [16], which was reflected in the severe patho-
logical injury found at autopsy [17].
The Argentinian population was greatly affected dur-
ing the pandemic, with a total of 1,390,566 cases of
influenza-like illness requiring 14,034 hospitalizations.
Of the 11,746 confirmed cases of patients infected with
the new strain, 617 died [18]. This represents a death
rate per infection of 4.3% in hospitalized cases; an inter-
mediate figure compared to 3.6% in Brazil, 1.2% in
Chile, and approximately 6% in Uruguay, Colombia and
Venezuela [19]. It should be noted that these numbers
reflect great uncertainty, particularly with regard to case
diagnosis. Lack of testing of mild disease and difficulties
due to laboratory overload have also been well described
[15,20]. These general problems have been acknowl-
edged by experts [21].
The severity of disease was rapidly perceived by health
authorities and scientific societies. Hence, a committee
of experts of the Argentinian Society of Intensive Care
Medicine decided to focus on the most acutely ill
patients: those presenting with diffuse viral pneumonitis
requiring mechanical ventilation. They designed an epi-
demiological study, recently-published, to determine risk
factors and outcomes [15]; this is one of many series up
to the present that have described epidemiological and
clinical aspects of the 2009 influenza A (H1N1) pan-
demic [6-15].
There remains, however, a paucity of data published
on physiological evolution during ICU stay [22]. This
present study, concurrently planned with the first by the
same committee of experts, thus aims to provide such
information. Our objectives were: first, to characterize
alterations of oxygenation, respiratory mechanics and
the use of mechanical ventilation; second, to explore
compliance with protective lung ventilation; and, finally,
to assess the evolution of laboratory findings and organ
dysfunctions throughout the course of the disease.
Materials and methods
This was a multicenter, inception cohort study that
included patients aged > 15 years admitted to the ICU
with a previous history of influenza-like illness, evolving
to acute respiratory failure that required mechanical
ventilation during the 2009 winter in the Southern
Hemisphere. These patients had confirmed or probable
d i s e a s ec a u s e db yt h e2 0 0 9i n f l u e n z aA( H 1 N 1 )v i r u s
a n dw e r ei n c l u d e di nt h eR e g i s t r yo fC a s e so ft h e
Argentinian Society of Intensive Care Medicine (SATI),
created to characterize local aspects of the pandemic.
On 27 June 2009, a form to collect online epidemiologi-
cal data was posted on the official SATI website. A
detailed description and analysis of this information was
recently published [14].
There was also an optional, more comprehensive case-
report form to complete, developed by experts of the
SATI’s Respiratory Committee for recording certain pre-
specified variables throughout ICU stay, which included
mechanical ventilation (MV), respiratory mechanics,
oxygenation, blood chemistry and organ failure vari-
ables. This information was collected over 10 days and
is analyzed in the present study.
Patients were characterized as confirmed, probable or
possible cases of 2009 influenza A (H1N1) [20] accord-
ing to the findings in the respiratory samples collected
on admission. Some specimens, however, were not ana-
lyzed because laboratories soon became overloaded,
especially at the beginning of the pandemic. As of 25
September 2009, the weekly update of the Ministry of
Health reported that in patients ≥5 years with influenza-
like illness, the 2009 influenza A (H1N1) virus had dis-
placed other respiratory viruses in 93.4% of the samples
processed [23,24]. As a result of this, probable and sus-
pected cases were considered as caused by the novel
virus and were so included in the study.
We collected dates of hospital and ICU admission,
and of MV onset; demographics; risk factors for influ-
enza A; actual weight; height; severity of illness (Acute
Physiology And Chronic Health Evaluation II, APACHE
II), organ failures (Sequential Organ Failure Assessment,
SOFA); type of MV used, as noninvasive (NIV) and
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(IBW, ml/kg) and body mass index (BMI) were calcu-
lated; obesity was defined as a BMI > 30.
At MV onset (Day 0) and on Days 3, 7 and 10, until
death or discharge, whichever occurred first, we
recorded: (1) MV-related variables. (2) MV modes:
volume-controlled ventilation (VCV); pressure-con-
trolled ventilation (PCV); bilevel mode; pressure support
v e n t i l a t i o n( P S V ) ;o t h e r .( 3 )T i d a lv o l u m e( V t ,i nm l / k g
of IBW) (4) Pressures: peak, plateau pressures, total
positive end-expiratory pressure (PEEP) and driving
pressure (plateau pressure - PEEP), in cmH2O. (5) Static
compliance (ml/cmH2O). (6) Respiratory rate (RR). (7)
Inspired oxygen fraction (FIO2). (8) Use of adjuvants of
MV: recruitment maneuvers, prone positioning, or tra-
cheal gas insufflations. (9) Use of NIV: duration (hours);
requirement of intubation; types of interfaces and of
ventilators used (Bilevel/conventional). (10) Date of
extubation; use of NIV for extubation failure, need of
reintubation.(11) Date of tracheostomy 10. (12) Blood
gases and acid-base variables. (13) PaO2/FIO2 relation-
ship. (14) Lung infiltrates in CXR (in quadrants). (15)
Use of oseltamivir, corticosteroids and neuromuscular
blockers. (16) Blood chemistry. (17) Daily fluid balance.
(18) SOFA score. (19) Cause of death.
The main outcome measure was hospital mortality;
secondary outcomes were length of MV, of ICU
(LOSICU) and of hospital (LOSHOSP) stays.
In case of missing observations, local study coordina-
tors were contacted to provide the corresponding values.
Proportions were calculated as percentages of existing
data.
No assumptions for missing data were made.
Statistical analysis
Statistical analysis was performed with SPSS 17.0 (SPSS
Inc., Chicago, IL, USA). Data were analyzed for the
entire population; for the subgroups of survivors vs.
non-survivors; and for patients receiving NIV on admis-
sion vs. those who did not. Descriptive statistics used
were: mean ± standard deviations (SD) and median and
25-75% interquartile ranges (IQR) for continuous data
of normal and non-normal distribution, respectively;
and percentages for categorical data. Differences
between subgroups were analyzed with unpaired t test,
Mann-Whitney U test, and Chi-square tests, as appro-
priate. A P-value of <.05 was considered statistically sig-
nificant. A Kaplan-Meier curve was constructed to
evaluate survival over the follow-up period.
Over time, normally distributed data were analyzed
with two-way repeated measures of ANOVA. At the
pre-specified time points, differences within the entire
group and subgroups, and between subgroups, were
tested using paired and unpaired t tests, respectively.
In non-normally distributed data, differences over time
within the entire group and the subgroups were ana-
lyzed with Friedman’s and Wilcoxon tests. Comparisons
between subgroups at the pre-specified time points were
tested with Mann-Whitney U test. The Bonferroni cor-
rection was used to adjustments for multiple
comparisons.
The local Institutional Review Boards waived the need
for informed consent, given the general lack of knowl-
edge on the clinical and outcome characteristics of the
ongoing pandemic and to the non-interventional study
design.
Results
General characteristics (Table 1)
Between 6 June and 28 August 2009, the SATI’s online
Registry included 337 patients admitted to 35 ICUs
with confirmed/probable/possible diffuse viral pneumo-
nitis caused by influenza A (H1N1), with acute respira-
tory failure requiring MV (14). Of these, 178
consecutive patients admitted to 20 ICUs were fol-
lowed over time, and are presented in this study. To
address any potential concern that unconfirmed cases
could belong to a different population of patients, we
performed a sensitivity analysis of clinical and outcome
characteristics data after exclusion of these patients.
The results of this analysis did not differ from those of
the primary assessments, so the 178 patients are con-
sidered for evaluation.
Briefly, patients were middle-aged, with no gender
preponderance; they had a history of symptoms of
nearly one-week duration and were ventilated at 1 [0 to
-2] day after hospital admission. Pre-existent respiratory
diseases, obesity, and diseases causing immunosuppres-
sion were the most frequent comorbid conditions; and
prevalence of pregnancy was higher than in the general
population, as expected [25]. Non-survivors were sicker
on admission; duration of previous symptoms was
longer; and organ failures were more severe. Obesity
and immunosuppression were significantly more fre-
quent as predisposing conditions. Ninety-three patients
survived (52%) (See Figure 1).
Clinical and mechanical ventilation-related variables
(Table 2)
During the study period, the entire group had Vt values
between 7.8 to 8.1 ml/kg of IBW, with plateau pressures
remaining always < 30 cmH2O. Non-survivors displayed
a trend towards lower Vt and higher plateau pressures,
which differed significantly from survivors only at Day
7. Intermediate PEEP levels were used, and decreased in
survivors from Day 3 onwards. Driving pressures were
similar over time in all patients; only at admission did
non-survivors exhibit higher values.
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patients and in survivors. It remained, however, < 200 in
the whole group throughout the entire ICU stay due to
non-survivor values. Non-survivors displayed signifi-
cantly lower PaO2/FIO2 at all time points.
Lung infiltrates (in quadrants) peaked at day 3 (3.1 ±
1 . 0v s .2 . 9±1a tD a y0 ,P < 0.01) and then decreased
during the study in the entire group, especially at Day
10 (2.8 ± 1.1, P <0 . 8 3v s .D a y0 ) ,w h i c hr e f l e c t e dt h e
improvement in survivors (3.1 ± 1.0 at Day 3 vs. 2.9 ±
1.0 at Day 10, P < 0.01).
In Figure 2, the utilization of ventilation modes and
rescue therapies in the entire group are shown. Briefly,
PCV use equaled VCV at Day 10, preceded by deteriora-
tion in oxygenation and respiratory mechanics: PaO2/
FIO2 78 ± 24 vs. 128 ± 33, (P = 0.03); PaCO2 44 ± 4 vs.
35 ± 3 mmHg (P = 0.04); pH 7.29 ± 0.03 vs. 7.39 ± 0.05
(P =0 . 0 5 ) ,a n dp l a t e a up r e s s u r e so f3 0±2v s .2 5±3
cmH2O( P = 0.03). Recruitment maneuvers became sig-
nificantly more common in non-survivors at Day 3
(46%, vs. 29% in survivors; P = 0.03), as did prone posi-
tioning (24%, vs. 14%; P = 0.001). After that, only prone
positioning remained significantly more used in non-
survivors (at Day 7: 38%; vs. 14%, P = 0.004; and at Day
10: 25%; vs. 5%, P = 0.02). Six patients received tracheal
gas insufflation; only one survived. Neuromuscular
blockers were prescribed in 18% of patients on admis-
sion; and their use was subsequently more frequent in
n o n - s u r v i v o r s( D a y3 :1 4 %v s .8 % ,P = 0.02; and Day 7:
14% vs. 8%, P = 0.04).
The main causes of death were refractory hypoxemia
(64%); followed by multiorgan dysfunction syndrome
(15%) and shock (10%). Prolonged mechanical ventila-
tion and long ICU and hospital stays were frequent
(Table 1). Tracheostomy was performed in 29 patients
(16%) at Day 14 [11-21].
Table 1 Baseline characteristics at admission of the entire group, and comparisons between survivors and non-
survivors
All (n = 178) Survivors (n = 93; 52%) Non-survivors (n = 85; 48%) P-value
Age 44 ± 15 45 ± 16 43 ± 15 0.36
Male gender 98 (55%) 49 (53%) 49 (58%) 0.44
APACHE II 18 ± 7 17 ± 6 20 ± 7 0.001
SOFA 4 (5 to 8) 3 (5 to 7) 6 (4 to 8) 0.000
Days of symptoms 6.7 ± 4.3 5.8 ± 3 7.5 ± 5 0.014
BMI 28 ± 8 28 ± 6 29 ± 10 0.32
Obesity
1 46 (26%) 17 (18%) 29 (34%) 0.016
COPD 28 (16%) 16 (17%) 12 (14%) 0.57
Asthma 10 (6%) 6 (6%) 4 (5%) 0.61
Other respiratory disease 5 (3%) 1 (1%) 4 (5%) 0.14
Chronic heart failure 10 (6%) 3 (3%) 7 (8%) 0.15
Other cardiac disease 8 (4%) 6 (6%) 2 (2%) 0.19
Ethilism/alcoholism 12 (7%) 8 (9%) 4 (5%) 0.30
Chronic hepatic disease 7 (4%) 1 (1%) 6 (7%) 0.04
Diabetes 16 (9%) 5 (5%) 11 (13%) 0.08
Chronic renal failure 13 (7%) 5 (5%) 8 (9%) 0.31
Immunosupression
2 29 (16%) 10(11%) 19(22%) 0.04
Pregnancy 16 (9%) 7 (8%) 9 (11%) 0.47
Previous seasonal influenza vaccination 4 (4%) 2 (2%) 2 (2%) 0.93
Confirmed cases by RT-PCR testing 95 (53%) 49 (53%) 46 (54%) 0.85
Oseltamivir use
3 174 (98%) 91 (98%) 82 (67%) 0.58
Corticosteroid use
4 75 (42%) 40% 45% 0.51
Length of MV 10 (6 to 17) 11 (6 to 19) 10 (4 to 16) 0.05
LOSICU 12 (7 to 19) 14 (10 to 22) 10 (4 to 16) < 0.001
LOSHOSPITAL 16 (10 to 23) 21 (14 to 38) 11 (6 to 18) < 0.001
BMI, body mass index; ICU, intensive care unit; LOSICU, length of stay at the ICU, in days; LOSHOSPITAL, length of stay at the hospital, in days; MV, mechanical
ventilation
1 Obesity was defined as a BMI > 30
2 Includes neoplasia, infection by human immunodeficiency virus, and autoimmune disease.
3 For corresponding doses, see reference 14.
4 Corticosteroids were prescribed in 36% of patients for septic shock as 300 mg/day of hydrocortisone. Ten percent received metilprednisolone for persistent
ARDS; 3% for other reasons, and 2% were pregnant patients receiving antenatal dexametasone to accelerate maturation of fetal lungs.
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Arterial pH increased over time in the whole cohort and in
both subgroups, perhaps secondary to general resuscitation
measures. Despite this, non-survivors displayed significantly
lower pH at all time points, owing to changes in base excess
on Days 0 and 3, and to pCO2 elevations thereafter.
Respiratory rates remained unchanged, only increasing at
Day 10 in non-survivors; nevertheless, this corresponded to
the highest pCO2 values, indicating the more severe respira-
tory compromise. Bicarbonate paralleled pH behavior.
Changes in fluid balance did not show clear trends:
only at Day 10 they decreased significantly, expressing
survivors’ behavior.
Use of noninvasive ventilation (Tables 4 and 5)
Forty-nine patients (28%) underwent a trial of NIV on
admission; they were significantly less ill and had a
lower incidence of immunosuppression. Oxygenation
and outcome variables were similar to those of patients
not receiving NIV.
Sixty-one percent of patients (n = 30) receiving NIV
survived; duration of NIV was of 8 (2 to 18) hours.
There were no differences between survivors and non-
survivors in the duration of the procedure, or in the
type of interface or respirator used. Of note, most
patients on NIV (46 out of 49; 94%) had to be intubated
and ventilated invasively for hypoxemic failure. Charac-
teristics associated to NIV success/failure are shown in
Table 5.
NIV was also used for treating post-extubation
respiratory failure in 12 of 178 patients (7%), with suc-
cess (reintubation not needed) in 8 cases (66%).
Blood chemistry and organ failures
The most consistent changes over time were found in
platelet count, which increased significantly in the whole
cohort (P < 0.000 for Days 3, 7 and 10 vs. Day 0), sec-
ondary to elevations in survivors. At all time points, pla-
telets differed between survivors and non-survivors.
Conversely, white blood cell count showed a progressive
Figure 1 Kaplan-Meier survival curve of the 178 patients with 2009 Influenza A (H1N1).
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10 vs. Day 0), due to elevations in non-survivors.
Creatine-kinase and markers of liver injury (alanine/
aspartate aminotransferases, serum bilirubin; not shown)
were mildly elevated and displayed no substantial
changes. On the contrary, lactate-dehydrogenase levels
were significantly higher in non-survivors throughout
the study. Creatinine levels were stable over the period,
but were significantly higher in non-survivors on Days 0
and 3. Finally, SOFA score diminished over time in all
patients (P < 0.000 for Days 7 and 10 vs. Day 0), as a
result of the decrease in survivors. SOFA was signifi-
cantly lower in survivors throughout the study.
In Figure 3, the differences between survivors and
non-survivors are displayed.
Discussion
We report on a large, prospective cohort of 2009 influ-
enza A (H1N1) patients that were mechanically venti-
lated for acute respiratory failure due to diffuse
pneumonitis during the pandemic in Argentina. Though
most were middle-aged, previously healthy adults,
patients with preexistent lung disease, immunosuppres-
sion, obesity and pregnancy were also affected. Mortality
was high and evolution to chronic critical illness was
common, as shown by prolonged mechanical ventilation,
high needs of tracheostomy, and lengthened ICU and
hospital stays.
Patients had characteristically a history of protracted
symptoms and displayed severe compromise of oxygena-
tion compatible with ARDS throughout the study per-
iod, which only improved in survivors. At all time
points, PaO2/FIO2 differed significantly between survi-
vors and non-survivors, requiring higher FIO2 and PEEP
in this last subgroup. Yet the levels of applied PEEP
were only in the intermediate range, similar to mean
values of 8.7 cmH2O of PEEP in an international study
on mechanical ventilation [26], which may explain the
relatively high FIO2 used in our study. Driving pressures
were similar in both subgroups most of the time, sug-
gesting an intention to limit alveolar excursion as part
of a protective strategy.
It is striking that, as has been described in similar stu-
dies on mechanical ventilation performed during the
2009 influenza A (H1N1) pandemic [6,7], tidal volumes
used were between 7.5 and 8.3 ml/kg IBW, certainly
higher than the 6 ml/kg demonstrated as being lung-
protective [27]. Indeed, barriers to implementing low-
tidal volume have been identified and might explain
physician behavior [28]. Despite this, plateau pressures
did remain below 30 cmH2O [29], indicating that lung
compliance might have been preserved. Perhaps
Table 2 Variables related to mechanical ventilation in all patients, and comparison between survivors and non-
survivors.
Day 0 Day 3 Day 7 Day 10
All S NonS P All S NonS P All S NonS P All S NonS P
N 178 93 85 152 89 63 129 80 42 73 38 35
Tidal volume
(ml/kg of
IBW)
7.8 ±
2
8.0 ±
2
7.7 ±
2
.35 7.9 ± 2 8.0 ± 2 7.8 ±
2
.46 7.9 ± 2 8.2 ± 2 7.5 ±
1
.02 8.1 ± 2 8.3 ± 2 7.9 ±
2
.35
Plateau
pressure
(cmH2O)
26 ±
7
25 ± 6 27 ±
8
.09 24 ± 7 24 ± 6 26 ± 8 .10 24 ± 7 23 ± 6 27 ±
8
.01 25 ± 8 24 ± 7 26 ± 8 .16
PEEP. (cm
H2O)
10 (7
to 14)
10 (7
to 14)
10 (8
to 14)
.34 10 (7
to 14)
10 (7
to 12)
12 (7
to 14)
.05 10 (6
to 14)
8
a (5
to 12)
12 (8
to 15)
.003 10 (6
to 14)
8
b (6
to 12)
12 (8
to 15)
.008
Driving
Pressure (cm
H2O)
16 ±
6
15 ± 5 17 ±
6
..05 15 ± 6 14 ± 5 16 ± 6 .16 15 ± 6 14 ± 5 16 ±
7
.26 15 ± 7 14 ± 5 16 ± 8 .21
Respiratory
rate (cycles/
min)
21 ±
5
21 ± 5 21 ±
4
.66 21 ± 5 20 ± 4 22 ± 5 .22 21 ± 5 20 ± 4 22 ±
5
.15 20 ± 6 20 ± 5 23 ± 6 .03
PaO2/FIO2 136
(85 to
204)
146
(110
to
215)
125
(71 to
197)
.02 178
a
(125 to
251)
220
a
(156 to
287)
134
(84 to
185)
<
0.001
195
a
(142 to
260)
230
a
(172 to
292)
144
(88 to
190)
<
0.001
172
a
(109 to
235)
212
a
(164 to
270)
123
(80 to
160)
<
0.001
FIO2 (%) 80 (25
to
100)
70 (50
to
100)
100
(70 to
100)
<
0.001
60
a
(40 to
70)
50
a
(40 to
60)
65
a
(50 to
100)
<
0.001
50
a
(40 to
65)
50
a
(40 to
55)
60
a
(45 to
85)
<
0.001
50
a
(41 to
70)
47
a
(40 to
50)
80
a
(50 to
100)
<
0.001
Data are presented as means ± standard deviations, and medians and (IQR)
Vt, Tidal volume. IBW, predicted body weight. S, Survivors. NonS, Non-survivors. P, Intergroup comparisons (between survivors vs. non-survivors) at each day are
shown.
For intragroup comparisons over time: Days 3, 7 and 10 are compared to Day 0 values, in all patients, in survivors and in non-survivors.
a P <.001;
b P <.01
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tidal volumes [30] since it still remains unclear which
should be limited to avoid ventilator-induced lung injury
[31]. We, like others [6,7,32,33], could not find
differences in utilized tidal volumes between survivors
and non-survivors. Even so, non-survivors tended to dis-
play lower values, probably reflecting physician efforts to
intensify protective ventilation strategies in the most
A
B
Figure 2 Modes of mechanical ventilation (A). Use of adjuvants (B). All refer to the entire group.
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Page 7 of 12severely compromised. Some researchers [34,35] have
suggested that allowing higher tidal volumes in a popu-
lation of young and previously healthy patients with
strong ventilatory drive might reveal an attempt to
restrain heavy sedation and neuromuscular blocker use.
Notwithstanding this, we believe that these findings may
also represent clinicians’ inadequate prescription, as
described in other scenarios [36].
Not unexpectedly, VCV was the most common venti-
lator mode used. PCV use increased throughout the
study period, peaking at Day 10. This is in contrast with
the recently identified trend towards decreased PCV uti-
lization. Transition to PCV mode was associated with
preceding physiological worsening, so clinicians might
have perceived PCV utilization as part of a global lung-
protective strategy [37].
Refractory hypoxemia was the main cause of death. As
in other studies [6,7,11], rescue therapies were fre-
quently applied, with utilization highest 72 hours after
admission. Recruitment maneuvers and prone position-
ing were the primary adjuvants utilized; ECMO and
HFOV are currently not available in Argentina. A
Table 3 Oxygenation and acid-base variables, and fluid balance in all patients, and in survivors and non-survivors.
Day 0 Day 3 Day 7 Day 10
All S NonS P All S NonS P All S NonS P All S NonS P
N 178 93 85 152 89 63 129 80 42 73 38 35
PaO2
(mmHg)
97 (71
to 124)
98 (76
to
120)
92 (67
to 129)
.50 94 (76
to
122)
98 (79
to 105)
87 (72
to 117)
.06 96 (79
to 115)
104 (84
to 125)
81 (73
to 102)
.001 96 (73
to 15)
106 (76
to 118)
84 (72
to 110)
.06
PaCO2
(mmHg)
44 ±
14
43 ±
12
46 ± 15 .22 44 ±
13
43 ±
13
46 ± 13 .14 47 ±
11
44 ±
10
51 ± 11 .02 47 ± 13 42 ±
10
52 ± 14 .001
Arterial pH 7.29 ±
0.1
7.31 ±
0.1
7.27 ±
0.1
.007 7.34 ±
0.1
a
7.37 ±
0.1
7.29 ±
0.1
c
.004 7.36 ±
0.1
a
7.39 ±
0.1
7.33 ±
0.1
.002 7.37 ±
0.1
c
7.41 ±
0.1
7.32 ±
0.1
.002
HCO3
(mEq/L)
21 ± 5 20 ± 6 22 ± 5 .16 24 ± 5
b
24 ± 5
a
22 ± 5 .02 27 ± 5
a
27 ± 5 28 ± 5
b .55 27 ± 5
c 27 ± 5 28 ± 7 .75
Fluid
balance
(ml/day)
785
(130;
1,802)
715
(98;
1,810)
1,000
(170;
1,800)
.99 1,050
(74;
210)
695
(-86;
2,025)
1,350
(505;
2,560)
.02 900
(-352;-
1,785)
700
(-470;-
1,770)
1,000
(-172;
1,810)
.75 129
b
(-673;
1,100)
0
b
(-800;
1,050)
757
(-450;
1,415)
.07
Data are presented as means ± standard deviations, and medians and (IQR)
NonS, Non-survivors. P, Intergroup comparisons (between survivors vs. non-survivors) at each day are shown. S, Survivors.
For intragroup comparisons over time: Days 3, 7 and 10 are compared to Day 0 values, in all patients, in survivors and in non-survivors.
a P < .001;
b P < .01;
c P < .05
Table 4 Characteristics of patients receiving non-invasive ventilation on admission, and comparison to those receiving
invasive ventilation
NIV (n = 49) Non-NIV (n = 129) P
Proportion of the entire population 28% 72%
Age (years) 40 ± 16 44 ± 15 0.26
Gender (male) 25 (51%) 73 (57%) 0.51
APACHE II 16 ± 6 19 ± 7 0.01
PaO2/FIO2 day0 129 (70 to 173) 141 (92 to 217) 0.12
PCO2 day0 42 (37 to 55) 42 (34 to 51) 0.23
COPD999 6/49 (12%) 22/129 (17%) 0.24
Asthma 2/49 (4%) 8/129 (6%) 0.58
CHF 1/49 (2%) 9/129 (7%) 0.20
Pregnancy 5/48 (10%) 11/128 (9%) 0.71
Immunosupression 3/49 (6%) 26/129 (20%) 0.03
Obesity
1 12/49 (24%) 34/129 (26%) 0.80
Hospital mortality 19 (39%) 66 (51%) 0.14
Total duration of mechanical ventilation (days)
2 12 (6 to 21) 10 (6 to 16)] 0.15
LOSICU 15 (8 to 25) 11 (7 to 17) 0.06
LOSHOSPITAL 19 (11 to 25) 16 (8 to 23) 0.06
CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; LOSICU, length of stay at the ICU, in days; LOSHOSPITAL, length of stay at the hospital, in
days; NIV, non-invasive ventilation
1 Obesity was defined as a BMI > 30
2 Refers to the sum of the duration of NIV plus the duration of invasive ventilation.
Ríos et al. Critical Care 2011, 15:R201
http://ccforum.com/content/15/4/R201
Page 8 of 12prolonged mechanical ventilation course was frequent as
reported elsewhere [6].
NIV was the first ventilation approach in 28% of cases,
with 94% later requiring invasive ventilation, as has been
documented in other studies [6,7,11]. These common
experiences should caution against delaying proper ven-
tilatory support in this group, given that rapid deteriora-
tion is common. A recent meta-analysis suggests that
NIV does not decrease the need for intubation, so evi-
dence to support its use in severe ARDS is questionable
[38]. In our study, improved outcomes with NIV could
be due to milder disease, evidenced by APACHE II. The
small number of patients that were not intubated pre-
cludes a statistical analysis; however, they were younger,
with less severe disease and better oxygenation.
Significant changes in fluid balance were late and
reflected changes in survivors. Negative fluid balances
could never be obtained, perhaps suggesting a continu-
ing need for hemodynamic support: 72% of patients pre-
sented with shock [14]. On the whole, fluid balances
remained between those achieved by “liberal” and “con-
servative” strategies of the fluids and catheters treatment
trial, depending on the day evaluated [39]. Thus far, it is
not clear whether the negative fluid balance has a causal
role in improving outcome in ALI/ARDS, or if it simply
expresses the global recovery of patients.
Another important finding was that arterial pH con-
sistently and significantly differed between survivors and
non-survivors, as described elsewhere [40,41]. During
the first 72 hours acidosis had a major metabolic com-
ponent, likely as a sign of hemodynamic impairment.
After the first week, respiratory acidosis ensued, indicat-
ing either the effects of protective ventilation, or merely
deterioration due to progressive shunt, profound ventila-
tion/perfusion mismatch and increased deadspace.
With respect to blood chemistry, the usual findings of
thrombocytopenia, leukocytosis and mildly elevated
creatine-kinase blood levels were present [21,42].
Regrettably, the lymphocyte count was not recorded. In
viral infections, thrombocytopenia occurred frequently.
Although the mechanisms by which the 2009 influenza
A (H1N1) virus causes thrombocytopenia are unknown,
its lack of resolution is a marker of poor prognosis.
Both leukocytosis and leucopenia have been found in
hospitalized patients with 2009 influenza A (H1N1)
[2,43]; in our study, persistent leukocytosis was asso-
ciated with increased mortality. LDH elevations have
been previously described in fatal cases [2], which corre-
sponded to our finding of higher LDH levels in non-sur-
vivors at all time points. Such elevations have also been
reported in seasonal influenza [44]. In experimental stu-
dies, increased LDH is a marker of human fetal mem-
brane cell apoptosis induced by influenza virus [45].
Finally, multiorgan failure was frequent, and predictably
more severe in non-survivors.
This study has several strengths: first, the clinical
characteristics and time course of pandemic 2009
influenza A (H1N1) are thoroughly described and ana-
lyzed. Second, data were collected prospectively in
consecutive patients and with a standardized case-
reporting form, representing a large, nationwide
cohort. Third, temporal patterns of mechanical ventila-
tion use, acid-base and blood chemistry variables, as
well as fluid balance and organ failures, are carefully
analyzed. Prognostic implications are highlighted.
Finally, we present the largest experience with NIV use
during the pandemic.
Study limitations include the focus on mechanically
ventilated patients, excluding less severe cases also
admitted to the ICU. Many cases could not be con-
firmed because laboratories were overwhelmed with
clinical samples, which is also described elsewhere
[7,14]. Data about transmission to healthcare workers
were not recorded, especially regarding NIV. Currently,
most information about its use during an epidemic
relies upon expert opinion [46].
Conclusions
In 178 patients with diffuse viral pneumonitis caused by
the 2009 influenza A (H1N1) virus admitted to the ICU
and followed over time, ARDS was the rule, requiring
high ventilation support and frequent use of rescue
therapies. Death, organ failures, and evolution to pro-
longed mechanical ventilation were common. In most
cases, noninvasive ventilation failed to prevent endotra-
cheal intubation. Finally, elevated LDH levels, lack of
recovery of platelet count and persistent acidosis and
leukocytosis in non-survivors behaved as prognostic
findings.
Table 5 Variables associated with noninvasive ventilation
success or failure.
NIV success (n =
3)
NIV failure (n =
46)
Prior duration of symptoms
(days)
3.6 ± 1.1 7.2 ± 3.8
Age 25 ± 10 42 ± 16
APACHE II 8 ± 3 17 ± 5
PaO2/FIO2 225 ± 115 140 ± 96
FIO2 0.35 ± 0.21 0.80 ± 0.22
Arterial pH 7.40 ± 0.03 7.31 ± 0.10
PaCO2 39 ± 2.5 46 ± 14
SOFA 2.6 ± 2 5.1 ± 2.7
LOSICU 13 (4 to 22) 16 (8 to 23)
LOSHOSPITAL 16 (4 to 27) 19 (12 to 32)
LOSICU, Length of stay at the ICU, in days; LOSHOSPITAL, Length of stay at the
hospital, in days; NIV, non-invasive ventilation. Due to the small number of
patients that did not require intubation and mechanical ventilation (n = 3),
statistical analysis was not performed.
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Page 9 of 12Key messages
￿ In 2009 influenza A (H1N1) patients, hospital admis-
sion with prompt indication of mechanical ventilation
- a marker of severe disease - was associated with a
history of symptoms of nearly one-week duration.
￿ An initial NIV trial was not effective to avoid intu-
bation in most patients; thus, this ventilation
approach should likely be discarded in this setting.
￿ Mortality and morbidity were frequent: death
was common and was mainly caused by persis-
tent, refractory hypoxemia. Prolonged mechanical
ventilation and ICU and hospital stays were
typical.
￿ pH, platelet count, LDH and SOFA differed signifi-
cantly between survivors and non-survivors over
time. Lack of recovery of platelet count and
For intragroup comparisons over time: *** P < .000; ** P < .001; * P < .05 
For intergroup comparisons at each time point: Ƿ P< .000; ¶ P< .05
Figure 3 Temporal patterns of platelet and white blood cell counts, lactic-dehydrogenase and serum creatinine.
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Page 10 of 12persistence of leukocytosis might be markers of poor
prognosis.
￿ Every effort should be done to increase adherence
to protective ventilation in the real world.
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